And pharma has broken up into 3 parts. CDMOs. We think the CDMO segment will remain under pressure in China. And we've sort of said, look, that piece of the business will not recover. If anything, the volume will go for contract manufacturing into Singapore or into the U.S. The emerging biotech or the pre-commercial biotech in China completely halted. That was 20% of the business of many of our customers.
That has completely halted and we don't expect that to come back for the balance of the year. So I hope that gives you a bit more color on what the assumptions are behind our China projections.